User login
Key clinical point: In patients with psoriatic arthritis (PsA), clinical disease activity improved rapidly with ixekizumab vs interleukin-12/23 inhibitors (IL-12/23i) and IL-23i; the improvements were similar to those with tumor necrosis factor inhibitors (TNFi) and Janus kinase inhibitors (JAKi).
Major finding: At 3 months, ixekizumab significantly improved clinical disease activity in patients with PsA compared with IL-12/23i and IL-23i (least square mean difference [LSMD], −8.4; 95% CI, −12.7 to −4.1). However, the improvements were similar to those with TNFi (LSMD, −0.2; 95% CI, −2.0 to 1.5) and JAKi (LSMD, 0.6; 95% CI, −2.3 to 3.5).
Study details: This 3-month interim analysis of the PRO-SPIRIT real-world study included 1192 patients with PsA (age, 18-80 years) across six countries who initiated or switched to a new biologic or targeted synthetic disease-modifying antirheumatic drug.
Disclosures: This study was sponsored by Eli Lilly and Company. Eight authors declared being employees and minor shareholders of Eli Lilly and Company. Several authors declared having ties with various sources, including Eli Lilly and Company.
Source: Kristensen LE, Ng KJ, Ngantcha M, et al. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. RMD Open. 2024;10:e004318. Source
Key clinical point: In patients with psoriatic arthritis (PsA), clinical disease activity improved rapidly with ixekizumab vs interleukin-12/23 inhibitors (IL-12/23i) and IL-23i; the improvements were similar to those with tumor necrosis factor inhibitors (TNFi) and Janus kinase inhibitors (JAKi).
Major finding: At 3 months, ixekizumab significantly improved clinical disease activity in patients with PsA compared with IL-12/23i and IL-23i (least square mean difference [LSMD], −8.4; 95% CI, −12.7 to −4.1). However, the improvements were similar to those with TNFi (LSMD, −0.2; 95% CI, −2.0 to 1.5) and JAKi (LSMD, 0.6; 95% CI, −2.3 to 3.5).
Study details: This 3-month interim analysis of the PRO-SPIRIT real-world study included 1192 patients with PsA (age, 18-80 years) across six countries who initiated or switched to a new biologic or targeted synthetic disease-modifying antirheumatic drug.
Disclosures: This study was sponsored by Eli Lilly and Company. Eight authors declared being employees and minor shareholders of Eli Lilly and Company. Several authors declared having ties with various sources, including Eli Lilly and Company.
Source: Kristensen LE, Ng KJ, Ngantcha M, et al. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. RMD Open. 2024;10:e004318. Source
Key clinical point: In patients with psoriatic arthritis (PsA), clinical disease activity improved rapidly with ixekizumab vs interleukin-12/23 inhibitors (IL-12/23i) and IL-23i; the improvements were similar to those with tumor necrosis factor inhibitors (TNFi) and Janus kinase inhibitors (JAKi).
Major finding: At 3 months, ixekizumab significantly improved clinical disease activity in patients with PsA compared with IL-12/23i and IL-23i (least square mean difference [LSMD], −8.4; 95% CI, −12.7 to −4.1). However, the improvements were similar to those with TNFi (LSMD, −0.2; 95% CI, −2.0 to 1.5) and JAKi (LSMD, 0.6; 95% CI, −2.3 to 3.5).
Study details: This 3-month interim analysis of the PRO-SPIRIT real-world study included 1192 patients with PsA (age, 18-80 years) across six countries who initiated or switched to a new biologic or targeted synthetic disease-modifying antirheumatic drug.
Disclosures: This study was sponsored by Eli Lilly and Company. Eight authors declared being employees and minor shareholders of Eli Lilly and Company. Several authors declared having ties with various sources, including Eli Lilly and Company.
Source: Kristensen LE, Ng KJ, Ngantcha M, et al. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study. RMD Open. 2024;10:e004318. Source